Radiolabeled BF3-BPA Boron Carrier for Accurate BNCT Distribution Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing boron neutron capture therapy (BNCT) relies on boron-carrying agents like 4-Boronic acid-L-phenylalanine (BPA) for tumor treatment, but the distribution of these agents is difficult to accurately monitor using current PET imaging probes like 2-fluoro-4-L-boronophenylalanine (FBPA), leading to uncertainties in treatment planning due to structural differences between the probe and therapeutic drug.
Innovation Solution
Development of a novel boron-carrying agent, BF3-BPA, which can be radiolabeled with 18F to maintain a consistent chemical structure for PET imaging and BNCT, incorporating two boron atoms for enhanced delivery and accuracy, utilizing selective trifluoroboration and hydrolysis to ensure chemical stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If FBPA is used as a PET probe to simulate BPA distribution, then tumor imaging capability is improved, but measurement precision deteriorates due to structural differences between probe and therapeutic drug
Solution Approach 1:
The patent applies multi-functionality by designing a single molecule (BPA) that serves both as a therapeutic agent for BNCT and as a PET imaging probe. By incorporating 18F radiolabeling directly into the BPA structure, the same molecule performs dual functions: delivering boron for neutron capture therapy and providing real-time distribution monitoring through PET imaging, thereby eliminating the structural differences that cause measurement inaccuracy.
2Quantity of substance
If BPA is used for BNCT treatment, then tumor treatment efficacy is improved, but reliability deteriorates due to inability to accurately monitor in vivo concentration distribution
Solution Approach 1:
The patent implements feedback by using PET imaging to continuously monitor the in vivo concentration distribution of the radiolabeled BPA in real-time. This feedback information about actual drug distribution is then used to adjust and optimize the BNCT treatment plan, ensuring that the therapeutic neutron irradiation is precisely tailored to the actual boron distribution in the patient's body, thereby improving treatment planning accuracy and reliability.
3Difficulty of detecting and measuring
If FBPA-PET technology is used for pre-treatment diagnosis, then imaging capability is improved, but manufacturing precision deteriorates due to immature technology and structural differences
Solution Approach 1:
The patent applies parameter changes by modifying the BPA molecule only in terms of radiolabeling with 18F, while maintaining the core chemical structure and biological properties identical to therapeutic BPA. This minimal parameter change (adding radioactive label) enables PET imaging without altering the molecule's pharmacokinetics, transport, or tumor uptake characteristics, thus achieving both detection capability and chemical structure consistency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BF3-BPA provides accurate real-time distribution monitoring through PET imaging and efficient BNCT treatment by maintaining chemical consistency, enhancing boron delivery and treatment efficacy with reduced side effects and drug dosage.
Implementation Method 1
The positron-bearing electrons emitted from positron-decaying isotopes such as 11C and 18F quickly annihilate with surrounding widely-distributed negative-bearing electrons
Implementation Method 2
The positron-bearing electrons emitted from positron-decaying isotopes such as 11C and 18F quickly annihilate with surrounding widely-distributed negative-bearing electrons, which converts energy into two photons with energy of 511 keV in opposite directions
Implementation Method 3
The capture cross section of 10B for thermal neutrons is very high compared to the normal elements of human body composition. The capture reaction between thermal neutrons and 10B atoms makes the energy of high-energy a particles and Li particles generated only act on cancer cells of about 10 μm
Implementation Method 4
The capture reaction between thermal neutrons and 10B atoms makes the energy of high-energy a particles and Li particles generated
Data Source
AI summary
The present invention relates to a boron carrying agent for integrated tumor diagnosis and treatment, and a preparation method therefor and use thereof. Provided is a compound represented by formula I: wherein an R group is hydrogen or alkyl. A boron atom connected to the benzene ring may be 10B or natural boron, and at least one fluorine atom in —BF 3- is radiolabeled. The present invention generally relates to the fields of radiopharmaceuticals and nuclear medicine. The compound in the present invention can be used for a drug for integrated diagnosis and treatment in tumor diagnosis and BNCT treatment, and by means of the same chemical structure, a reliable distribution result of a drug in vivo is provided.